Table 3.
Polysomnography parameters.
| Reboxetine | Placebo | Reb-Oxy | P value | |
|---|---|---|---|---|
| Supine AHI (events/h) | 43 ± 20 | 46 ± 15 | 42 ± 25 | .578 |
| Supine sleep (%TST) | 49 (27–80) | 52 (31–94) | 54 (35–71) | .121 |
| NREM AHI (events/h) | 31 ± 15 | 35 ± 17 | 32 ± 17 | .253 |
| Obstructive apnea index (events/h) | 0 (0–3) | 3 (0–10) | 0 (0–3) | .072 |
| 3% ODI (events/h) | 8.9 (2.1–21.1) | 13.1 (10.1–35.5) | 13.1 (2.0–20.7) | .029*† |
| Snoring index (snores/h)‡ | 341 ± 179 | 469 ± 176 | 252 ± 177 | .001*† |
| Arousal index (events/h) | 33 ± 13 | 32 ± 12 | 30 ± 12 | .609 |
| Total sleep time (min) | 376 ± 44 | 391 ± 51 | 400 ± 38 | .218 |
| Sleep efficiency (%TIB) | 79 ± 10 | 80 ± 10 | 85 ± 6 | .113 |
| Wake after sleep onset (min) | 90 ± 35 | 83 ± 42 | 64 ± 28 | .105 |
| Sleep stage (% of TST) | ||||
| N1 | 25 ± 17 | 21 ± 11 | 27 ± 14 | .185 |
| N2 | 56 ± 16 | 45 ± 11 | 56 ± 14 | .003*† |
| N3 | 18 ± 8 | 21 ± 11 | 16 ± 7 | .100 |
| REM | 2 ± 2 | 13 ± 7 | 2 ± 4 | <.001*† |
| Morning measurements | ||||
| Heart rate (beats/min) | 83 ± 14 | 69 ± 11 | 83 ± 13 | <.001*† |
| Systolic blood pressure (mm Hg) | 134 ± 21 | 134 ± 15 | 134 ± 17 | .984 |
| Diastolic blood pressure (mm Hg) | 89 (83–96) | 88 (79–91) | 90 (83–97) | .103 |
AHI values refer to AHI scored using 3% desaturation criteria. Data are presented as mean ± SD or median (interquartile range) as appropriate. *Reboxetine vs placebo pairwise comparison P < .05. †Reboxetine+oxybutynin vs placebo pairwise comparison P < .05. ‡n = 13. Three participants’ snoring data were incomplete and therefore were not included in the analysis. AHI = apnea-hypopnea index, N1 = stage 1 sleep, N2 = stage 2 sleep, N3 = stage 3 sleep, NREM = nonrapid eye movement sleep, ODI = oxygen desaturation index, Reb-Oxy = reboxetine+oxybutynin, REM = rapid eye movement sleep, TIB = time in bed, TST = total sleep time.